Magdalena Tyrpien

Magdalena Tyrpien is Chief Business Officer at Forge Biologics. Her experience spans corporate business development, strategic planning, and investor relations in the biotechnology and venture capital industries across a range of therapeutics areas and stages of development, culminating in the acquisition of Forge by Ajinomoto Co. Previously, she was Director of Business Development at PTC Therapeutics, a global commercial stage small molecule and gene therapy biopharmaceutical company. Ms. Tyrpien was directly responsible for leading efforts around licensing and acquisition of assets and led a $268M company acquisition with a Phase III ready asset for patients with PKU. Prior to joining PTC, she served as Director of Corporate Strategy and Business Development at Abeona Therapeutics, a gene and cell therapy company. Ms. Tyrpien earned her B.A. from Montclair State University and an M.B.A. from the University of Liverpool (UK).